217 related articles for article (PubMed ID: 10877054)
1. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
3. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
Kraut EH
Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
[TBL] [Abstract][Full Text] [Related]
4. Pentostatin (Nipent) in T-cell lymphomas.
Kurzrock R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
[TBL] [Abstract][Full Text] [Related]
5. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
Weiss MA
Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
[TBL] [Abstract][Full Text] [Related]
6. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
7. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
10. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Tsimberidou AM; Giles F; Duvic M; Fayad L; Kurzrock R
Cancer; 2004 Jan; 100(2):342-9. PubMed ID: 14716770
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.
Greiner D; Olsen EA; Petroni G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):950-5. PubMed ID: 9204061
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group.
Tobinai K; Shimoyama M; Inoue S; Takayasu S; Mikuni C; Kozuru M; Oda S; Nakajima H
Jpn J Clin Oncol; 1992 Jun; 22(3):164-71. PubMed ID: 1518164
[TBL] [Abstract][Full Text] [Related]
15. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with 2'-deoxycoformycin.
Catovsky D
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S103-7. PubMed ID: 9137963
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders.
Goodman M
Semin Oncol; 2000 Apr; 27(2 Suppl 5):67-71. PubMed ID: 10877056
[TBL] [Abstract][Full Text] [Related]
18. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
19. Pentostatin (Nipent): a review of potential toxicity and its management.
Margolis J; Grever MR
Semin Oncol; 2000 Apr; 27(2 Suppl 5):9-14. PubMed ID: 10877045
[TBL] [Abstract][Full Text] [Related]
20. Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Byrd JC; Grever MR; Waselenko JK; Willis CR; Park K; Goodrich A; Lucas MA; Shinn C; Flinn IW
Semin Oncol; 2000 Apr; 27(2 Suppl 5):37-40. PubMed ID: 10877050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
